Results 191 to 200 of about 958,637 (251)

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Pharmacogenetic biomarkers for predicting therapeutic response to JAK inhibitors in rheumatoid arthritis. [PDF]

Adv Lab Med
Plasencia-Rodríguez C, Novella-Navarro M, Valdivieso Shephard JL, Martínez-Feito A, Reche-Yebra K, Juárez-García M, Villalba-Yllán A, Rubio-Lepe TS, Arias P, Collada Sánchez VL, Martin-López S, Losantos-García I, Borobia AM, Rosas-Alonso R.   +13 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. [PDF]

Cureus
Burashed KK, AlAbbasi FA.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence. [PDF]

Front Immunol
Wu Z, Jiang L, Zheng X, Zhou W, Wang Z, Xie W.   +5 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status. [PDF]

Front Med (Lausanne)
Parra-Moreno M, Ladehesa-Pineda L, Calvo-Gutierrez J, Cepas-Guitérrez FJ, Moreno-Caño E, Robustillo-Villarino M, Zúñiga-Vera A, Plasencia-Rodríguez C, Martinez-Feito A, Costa-Moya E, Taverner-Torrent D, Sainz-Comas L, Díaz-Torné C, Ruiz-Esquide V, Rojas C, Martin-de la Sierra Lopez L, Jiménez-Rodríguez L, Velasco-Sánchez D, Faré-García R, Juan-Mas A, Moreno-García MS, Acosta-Alfaro AV, Muñoz-Fernández S, Martín-López M, Zas R, Godoy-Navarrete J, Añon-Oñate I, Ortiz-Márquez F, Mena-Vázquez N, Estrada P, Ortega-Castro R, Escudero-Contreras A, López-Medina C.   +32 more
europepmc   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

JAK inhibitors in livedoid vasculopathy associated with thrombophilia and refractory to anticoagulation: report and literature review. [PDF]

An Bras Dermatol
Criado GJ, Criado PR, Lorenzini D, Miot HA.   +3 more
europepmc   +1 more source